Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Debt-to-Equity : 0.04 (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Integrated Diagnostics Holdings Debt-to-Equity?

Integrated Diagnostics Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.9 Mil. Integrated Diagnostics Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $2.6 Mil. Integrated Diagnostics Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $80.1 Mil. Integrated Diagnostics Holdings's debt to equity for the quarter that ended in Jun. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Integrated Diagnostics Holdings's Debt-to-Equity or its related term are showing as below:

IDGXF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.15 Max: 0.55
Current: 0.44

During the past 12 years, the highest Debt-to-Equity Ratio of Integrated Diagnostics Holdings was 0.55. The lowest was 0.00. And the median was 0.15.

IDGXF's Debt-to-Equity is ranked worse than
64.43% of 194 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs IDGXF: 0.44

Integrated Diagnostics Holdings Debt-to-Equity Historical Data

The historical data trend for Integrated Diagnostics Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integrated Diagnostics Holdings Debt-to-Equity Chart

Integrated Diagnostics Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.20

0.24

0.33

0.55

0.44

Integrated Diagnostics Holdings Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.04	0.55	0.07	0.04	0.44

Competitive Comparison of Integrated Diagnostics Holdings's Debt-to-Equity

For the Diagnostics & Research subindustry, Integrated Diagnostics Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integrated Diagnostics Holdings's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integrated Diagnostics Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Integrated Diagnostics Holdings's Debt-to-Equity falls into.

Integrated Diagnostics Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Integrated Diagnostics Holdings's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.13	+	31.018)	/	86.665
	=	0.44

Integrated Diagnostics Holdings's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.919	+	2.575)	/	80.062
	=	0.04

Integrated Diagnostics Holdings (OTCPK:IDGXF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Integrated Diagnostics Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Integrated Diagnostics Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Integrated Diagnostics Holdings PLC (OTCPK:IDGXF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IDHCl:UK IDHC:UK IDHC.CA:Egypt 8I8:Germany

Address

12 Castle Street, Saint Helier, JEY, JE2 3RT

Website

https://www.idhcorp.com

Integrated Diagnostics Holdings PLC is active in the healthcare sector. It is a fully integrated diagnostics service provider. It is a fully integrated diagnostics service provider operating through brands such as Al Borg and Al Mokhtabar in Egypt, as well as Biolab in Jordan and Ultralab and Al Mokhtabar Sudan in Sudan. The company specializes in diagnostic tests, ranging from basic tests, such as glucose testing for diabetes, to molecular tests for hepatitis and specialized DNA tests. The company operates in two segment- Contract Segment and Walk-in Segment. It derives majority of its revenue from services offered in Egypt.

Integrated Diagnostics Holdings (Integrated Diagnostics Holdings) Headlines

From GuruFocus

Equity Portfolio as a Savings Account

By Steven CHEN • 09-24-2021